The ISUP system of staging, grading and classification of renal cell neoplasia

Main Article Content

Hemamali Samaratunga
Troy Gianduzzo
Brett Delahunt

Keywords

Classification, Grading, International Society of Urological Pathology, ISUP, Kidney cancer, Renal neoplasia, Staging

Abstract

There have been significant changes in the staging, classification and grading of renal cell neoplasia in recent times. Major changes have occurred in our understanding of extra-renal extension by renal cell cancer and how gross specimens must be handled to optimally display extra-renal spread. Since the 1981 World Health Organization (WHO) classification of renal tumors, in which only a handful of different entities were reported, many new morphological types have been described in the literature, resulting in 50 different entities reported in the 2004 WHO classification. Since 2004, further new entities have been recognized and reported necessitating an update of the renal tumor classification. There have also been numerous grading systems for renal cell carcinoma with Fuhrman grading, the most widely used system. In recent times, the prognostic value and the applicability of the Fuhrman grading system in practice has been shown to be, at best, suboptimal. To address these issues and to recommend reporting guidelines, the International Society of Urological pathology (ISUP) undertook a review of adult renal neoplasia through an international consensus conference in Vancouver in 2012. The conduct of the conference was based upon evidence from the literature and the current practice amongst recognized experts in the field. Working groups selected to deal with key topics evaluated current data and identified points of controversy. A pre-meeting survey of the ISUP membership was followed by the consensus conference at which a formal ballot was taken on each key issue. A 65% majority vote was taken as consensus. This review summarizes the outcome and recommendations of this conference with regards to staging, classification and grading of renal cell neoplasia.

Abstract 7614 | PDF Downloads 1988 HTML Downloads 45011

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA Cancer J Clin. 2013; 63: 11-30. DOI: http://dx.doi.org/10.3322/caac.21166

2. Luke C, Sargent N, Pittman K, Price T, Roder D. Epidemiology of cancers of the kidney in an Australian population. Asian Pac J Cancer Prev. 2011; 12:2893-2899. PMid: 22393960

3. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Gr�nwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15:286-296. DOI: http://dx.doi.org/10.1016/S1470-2045(14)70030-0

4. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 10; 32:760-767. DOI: http://dx.doi.org/10.1200/JCO.2013.50.3961

5. Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, Motzer R, Michaelson MD. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014; 73:181-189. DOI: http://dx.doi.org/10.1007/s00280-013-2339-y

6. Bonsib SM, Gibson D, Mhoon M, Greene GF. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol. 2000; 24:451-458. DOI: http://dx.doi.org/10.1097/00000478-200003000-00015

7. Bonsib SM. The renal sinus is the principal invasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol. 2004; 28:1594-1600. DOI: http://dx.doi.org/10.1097/00000478-200412000-00007

8. Bonsib SM. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol. 2005; 174:1199-1202. DOI: http://dx.doi.org/10.1097/01.ju.0000173631.01329.1f

9. Thompson RH, Blute ML, Krambeck AE, Lohse CM, Magera JS, Leibovich BC, Kwon ED, Frank I, Cheville JC. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol. 2007; 31: 1089-1093. DOI: http://dx.doi.org/10.1097/PAS.0b013e31802fb4af

10. Bonsib SM. Macroscopic assessment, dissection protocols and histologic sampling strategy for renal cell carcinomas. Diagn Histopathol. 2008; 14:151-156. DOI: http://dx.doi.org/10.1016/j.mpdhp.2008.02.006

11. Sobin LH, Compton CC. TNM seventh edition: What's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010; 116:5336–5339.
DOI: http://dx.doi.org/10.1002/cncr.25537

12. Edge SB, Byrd DR, Carducci M, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.

13. Mostofi FK. International Histological Classification of Tumors No. 25: Histological Typing of Kidney Tumors. Geneva cortisone Word Health Organization; 1981.

14. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, St�rkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. J Pathol. 1997; 183:131-133. DOI: http://dx.doi.org/10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G

15. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.

16. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982; 6:655-663. DOI: http://dx.doi.org/10.1097/00000478-198210000-00007 PMid:7180965

17. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009 Jun; 22 Suppl 2:S24-36. DOI: http://dx.doi.org/10.1038/modpathol.2008.183

18. Goldstein NS. Grading of renal cell carcinoma. Urol Clin North Am. 1999; 26:637-642.
DOI: http://dx.doi.org/10.1016/S0094-0143(05)70204-4

19. Ficarra V, Martignoni G, Maffei N, Brunelli M, Novara G, Zanolla L, Pea M, Artibani W. Original and reviewed nuclear grade according to the Fuhrman system : a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer 2005; 103:68-75. DOI: http://dx.doi.org/10.1002/cncr.20749 PMid:15573369

20. Delahunt B, Egevad L, Montironi R, Srigley JR. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol. 2013; 37:1463-1468. DOI: http://dx.doi.org/10.1097/PAS.0b013e318299f14a

21. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P. ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013; 37:1469-1489. DOI: http://dx.doi.org/10.1097/PAS.0b013e318299f2d1

22. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37:1490-1504. DOI: http://dx.doi.org/10.1097/PAS.0b013e318299f0fb

23. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR. members of the ISUP Renal Tumor Panel. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013; 37:1505-1517. DOI: http://dx.doi.org/10.1097/PAS.0b013e31829a85d0

24. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013; 37:1518-1531. DOI: http://dx.doi.org/10.1097/PAS.0b013e318299f12e

25. Fleming S, Griffiths DF. Best Practice No 180. Nephrectomy for renal tumour; dissection guide and dataset. J Clin Pathol. 2005; 58:7-14. DOI: http://dx.doi.org/10.1136/jcp.2003.014159

26. Algaba F, Trias I, Scarpelli M, Boccon-Gibod L, Kirkali Z, Van Poppel H. Handling and pathology reporting of renal tumor specimens. Eur Urol. 2004; 45:437-443. DOI: http://dx.doi.org/10.1016/j.eururo.2003.11.026

27. Mehta V1, Mudaliar K, Ghai R, Quek ML, Milner J, Flanigan RC, Picken MM. Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat. Arch Pathol Lab Med. 2013; 137:1584-1590.
DOI: http://dx.doi.org/10.5858/arpa.2012-0485-OA PMid:23651149

28. Che M, Grignon DJ. Handling and reporting of tumor-containing kidney specimens.Clin Lab Med. 2005; 25:417-432. DOI: http://dx.doi.org/10.1016/j.cll.2005.01.009

29. Axwijk PH, Kluijt I, de Jong D, Gille H, Teertstra J, Horenblas S. Hereditary causes of kidney tumours. Eur J Clin Invest. 2010; 40:433-439. DOI: http://dx.doi.org/10.1111/j.1365-2362.2010.02270.x PMid:20534065

30. Verine J, Pluvinage A, Bousquet G, Lehmann-Che J, de Bazelaire C, Soufir N, Mongiat-Artus P. Hereditary renal cancer syndromes: an update of a systematic review. Eur Urol. 2010; 58:701-710. DOI: http://dx.doi.org/10.1016/j.eururo.2010.08.031

31. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012; 39:133-148. DOI: http://dx.doi.org/10.1016/j.ucl.2012.01.006

32. Kuroda N, Tanaka A, Ohe C, Mikami S, Nagashima Y, Sasaki T, Inoue K, Hes O, Michal M, Brunelli M, Martignoni G. Review of renal oncocytosis (multiple oncocytic lesions) with focus on clinical and pathobiologicalaspects Histol Histopathol. 2012; 27:1407-1412. PMid: 23018240

33. Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006; 30:141-153.
DOI: http://dx.doi.org/10.1097/01.pas.0000185382.80844.b1

34. Bonsib SM. Renal veins and venous extension in clear cell renal cell carcinoma. Mod Pathol. 2007; 20:44-53.
DOI: http://dx.doi.org/10.1038/modpathol.3800726 PMid:17170742

35. Zini L, Destrieux-Garnier L, Leroy X, Villers A, Haulon S, Lemaitre L, Koussa M. Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. J Urol. 2008; 179:450-454. DOI: http://dx.doi.org/10.1016/j.juro.2007.09.042

36. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005; 173:918-921.
DOI: http://dx.doi.org/10.1097/01.ju.0000153419.98715.24 PMid:15711327

37. Han KR1, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 2003; 169:899-903. DOI: http://dx.doi.org/10.1097/01.ju.0000051480.62175.35

38. Zhou M, Yang XJ, Lopez JI, Shah RB, Hes O, Shen SS, Li R, Yang Y, Lin F, Elson P, Sercia L, Magi-Galluzzi C, Tubbs R. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Am J Surg Pathol 2009; 33:1840-1849. DOI: http://dx.doi.org/10.1097/PAS.0b013e3181be22d1

39. Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006; 30:141-153.
DOI: http://dx.doi.org/10.1097/01.pas.0000185382.80844.b1

40. Aydin H, Chen L, Cheng L, Vaziri S, He H, Ganapathi R, Delahunt B, Magi-Galluzzi C, Zhou M. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010; 34:1608-1621. DOI: http://dx.doi.org/10.1097/PAS.0b013e3181f2ee0b

41. Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M, Griffin CA. Molecular confirmation of the t(6;11)(p21;q12) renal cell carcinomas in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinciopathologic spectrum. Am J Surg Pathol 2012; 36: 1516-1526.
DOI: http://dx.doi.org/10.1097/PAS.0b013e3182613d8f

42. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007; 31: 1578-1585.
DOI: http://dx.doi.org/10.1097/PAS.0b013e31804375b8

43. Gill AJ, Pachter NS, Chou A, Young B, Clarkson A, Tucker KM, Winship IM, Earls P, Benn DE, Robinson BG, Fleming S, Clifton-Bligh RJ. Renal tumors associated with germline SDHB mutations show distinctive morphology. Am J Surg Pathol 2011; 35: 1578-1585. DOI: http://dx.doi.org/10.1097/PAS.0b013e318227e7f4

44. Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011; 24: 430-442.
DOI: http://dx.doi.org/10.1038/modpathol.2010.213

45. Amin MB1, Gupta R, Ondrej H, McKenney JK, Michal M, Young AN, Paner GP, Junker K, Epstein JI. Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol 2009; 33: 393-400. DOI: http://dx.doi.org/10.1097/PAS.0b013e31818cb8f5

46. Suzigan S, Lopez-Beltran A, Montironi R et al. Multilocular cystic renal cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006; 125:217-222. DOI: http://dx.doi.org/10.1309/AH6F-C77P-YR2V-6YAY PMid:16393684

47. Murakami T, Sano F, Huang Y, et al. Identification and characterization of Birt-Hogg Dube associated renal carcinoma. J Pathol 2007; 211:524-31. DOI: http://dx.doi.org/10.1002/path.2139


48. Gobbo S, Eble JN, Delahunt B et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profile. Am J Surg Pathol 2010; 34:620-626. PMid: 20305535

49. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011; 35: 161-176. DOI: http://dx.doi.org/10.1097/PAS.0b013e318206f2a9

50. Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipomas with atypia; a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol 2010; 34:715-722. PMid: 20410812

51. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumors divided according to histological subtype. Pathology 2007; 39:459-465. DOI: http://dx.doi.org/10.1080/00313020701570061

52. Delahunt B, Srigley JR, Montironi R, Egevad L. Urological pathology comes of age. Pathology 2012; 44:389-390.
DOI: http://dx.doi.org/10.1097/PAT.0b013e3283562584

53. Delahunt B, Sika-Paotonu D, Bethwaite PB et al. Grading of clear cell renal cell carcinoma should be based upon nucleolar prominence. Am J Surg Pathol 2011; 135: 1134-1139. DOI: http://dx.doi.org/10.1097/PAS.0b013e318220697f

54. Delahunt B, McKenney JK, Lohse CM, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol 2013; 37:311-322. DOI: http://dx.doi.org/10.1097/PAS.0b013e318270f71c

55. Sukov WR, Lohse CM, Leibovich BC et al. Clinical and pathological features associated with prognosis in patients with renal cell carcinoma. J Urol 2012; 187:54-59. DOI: http://dx.doi.org/10.1016/j.juro.2011.09.053

56. Delahunt B. Sarcomatoid renal cell carcinoma: The final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1993; 31:185-190. DOI: http://dx.doi.org/10.1080/003130299104945

57. Chapman-Fredricks JR, Herrera L, Brancho J et al. Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analagous to sarcomatoid carcinoma. Ann Diagn Pathol 2001; 15:333-337.
DOI: http://dx.doi.org/10.1016/j.anndiagpath.2011.03.002

58. Delahunt B, Sika-Paotonu D, Bethwaite PB et al. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 2007; 31:957-960. DOI: http://dx.doi.org/10.1097/01.pas.0000249446.28713.53

59. Ficarra V, Martignoni G, Alfano G et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol 2006; 50;786-794. DOI: http://dx.doi.org/10.1016/j.eururo.2006.04.009

60. Delahunt B, Srigley JR, Montironi R, Egevad L. International Society of Urological Pathology (ISUP) Grading and Other Prognostic Factors for Renal Neoplasia. Eur Urol. In Press.